New developments on thromboxane and prostacyclin modulators. Part 1: Thromboxane modulators

J.-M. Dogné, X. de Leval, J. Hanson, M. Frederich, B. Lambermont, A. Ghuysen, A. Casini, B. Masereel, K.-H. Ruan, B. Pirotte, P. Kolh

Research output: Contribution to journalArticleAcademicpeer-review

80 Citations (Scopus)


The pathogenesis of numerous cardiovascular, pulmonary, inflammatory, and thromboembolic diseases can be related to arachidonic acid (AA) metabolites. One of these bioactive metabolites of particular importance is thromboxane A2 (TXA2). It is produced by the action of thromboxane synthase on the prostaglandin endoperoxide H2 (PGH2), which results from the enzymatic degradation of AA by the cyclooxygenases. TXA2 is a potent inducer of platelet aggregation, vasoconstriction and bronchoconstriction. It is involved in a series of major pathophysiological states such as asthma, myocardial ischemia, pulmonary hypertension, and thromboembolic disorders. Therefore, TXA2 receptor antagonists, thromboxane synthase inhibitors and drugs combining both properties have been developed by several pharmaceutical companies since the early 1980s. Several compounds have been launched on the market and others are under clinical evaluation. Moreover, the recent literature reported the interest of thromboxane modulators, which combine another pharmacological activity such as, platelet activating factor antagonism, angiotensin II antagonism, or 5-lipoxygenase inhibition. In this review, we will propose a description of the recently described thromboxane modulators of major interest from both a pharmacological and a chemical point of view. © 2004 Bentham Science Publishers Ltd.
Original languageEnglish
Pages (from-to)1223-1241
Number of pages19
Issue number10
Publication statusPublished - May-2004
Externally publishedYes


  • Arachidonic acid
  • Prostanoids
  • Thromboxane A2
  • Thromboxane receptor antagonist
  • Thromboxane synthase
  • Thromboxane synthase inhibitor

Cite this